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ABSTRACT
Background. Intraoperative analysis of sentinel lymph
nodes would enhance the care of early-stage oral squamous
cell carcinoma (OSCC). We determined the frequency and
extent of cytokeratin 19 (CK19) expression in OSCC pri-
mary tumours and surrounding tissues to explore the
feasibility of a ‘‘clinic-ready’’ intraoperative diagnostic test
(one step nucleic acid amplification—OSNA, sysmex).
Methods. Two cohorts were assembled: cohort 1, OSCC
with stage and site that closely match cases suitable for
sentinel lymph node biopsy (SLNB); cohort 2, HNSCC
with sufficient fresh tumour tissue available for the OSNA
assay ([50 mg). CK19 assays included qRT-PCR, RNA
in situ hybridisation (ISH), and immunohistochemistry
(IHC), as well as OSNA.
Results. CK19 mRNA expression was detected with vari-
able sensitivity, depending on method, in 60–80% of primary
OSCC tumours, while protein expression was observed in
only 50% of tumours. Discordance between different tech-
niques indicated that OSNA was more sensitive than qRT-
PCR or RNA-ISH, which in turn were more sensitive than
IHC. OSNA results showed CK19 expression in 80% of
primary cases, so if used for diagnosis of lymph node
metastasis would lead to a false-negative result in 20% of
patients with cervical lymph node metastases.
Conclusions. OSNA in its current form is not suitable for
use in OSCC SLNB due to inadequate expression of the
CK19 target in all case. However, the same assay tech-
nology would likely be very promising if applied using a
more ubiquitous squamous epithelial target.
Renewed interest in sentinel lymph node biopsy (SLNB)
for early-stage oral squamous cell carcinoma (OSCC) has
resulted from reassuring data with 95% negative predictive
value (NPV) and also recent trials reinforcing the survival
benefit of surgical neck staging.1–3 A significant drawback
of SLNB is that, in the event of a positive lymph node, a
costly (and more morbid) second surgical episode is
necessitated. This delay, mandated by serial examination of
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SLN, delays the commencement of adjuvant therapy and
creates additional patient distress. SLNB in OSCC would
be facilitated by intraoperative staging; however, frozen-
section analysis has been found to be somewhat insensitive,
certainly highly operator dependent, and has not found
general acceptance.4–6 PCR-based techniques have been
reported for head and neck squamous cell carcinoma
(HNSCC) but lack a ‘‘clinic-ready’’ platform.7,8
One-step nucleic acid amplification (OSNA) uses loop-
mediated isothermal amplification (LAMP), amplifying
RNA with high sensitivity, specificity, efficiency, and
rapidity under isothermal conditions.9 OSNA employs six
specially designed primers at eight sequences within CK19
mRNA subtending high sensitivity and specificity. In
breast cancer, OSNA has been validated to at least 96%
concordance with histopathology and has been widely
adopted and approved in UK NICE guidelines.10,11 OSNA
necessitates an additional 30–40 min operative time but
avoids second surgeries and accelerates commencement of
adjuvant therapies from 8.4 to 6.2 weeks.12
In HNSCC, the clinical potential of OSNA is unproven,
and careful validation is required. Although gene signatures
for OSCC or epithelial tissue have been developed with
sensitive RT-PCR using other target cytokeratins, or PVA/
EPCAM, the opportunity aroundCK19 is the availability of a
‘‘clinic-ready’’ diagnostic test with stringent quality assur-
ance.7,8 Several reports have shown that CK19 is a
component of the cytoskeleton of HNSCC and qRT-PCR for
cytokeratins appear sensitive and specific in detecting cer-
vical lymph node metastasis in HNSCC.8,13–15 CK19 OSNA
has been validated recently for lymph node staging in col-
orectal and stomach adenocarcinoma.16–19 The extent of
CK19 expression in HNSCC, and therefore whether OSNA
could have clinical utility, remains unproven.
Goda et al. analysed 213 HNSCC lymph nodes with
CK19 OSNA and suggested an overall accuracy of 94% per
node and 94% per patient.20 Matsuzuka et al. found a NPV
of 95.9% in HNSCC.21 Suzuki examined CK19 expression
in HSNCC, finding a lower rate of expression and sug-
gesting that clinical use of OSNA only in a selected subset
of HNSCC known to be CK19 positive.22 All three studies
were undertaken in a Japanese population with a variety of
stages and sites of HNSCC. For example, Goda et al. report
on cT1-4 and N0-3 OSCC and Matsuaka et al. report on a
combination of HNSCC sites and also include advanced
stages.20,21 Because SLNB is routinely offered only to cT1-
2N0 OSCC, these reports do not ideally reflect the target
clinical population in question. It remains uncertain if the
expression of CK19 is sufficiently high and uniform to
make the CK19 OSNA suitable for use in OSCC SLNB.
The purpose of this study was to establish the frequency
and extent of CK19 expression in primary OSCC and sur-
rounding, potentially contaminating, tissues. We established
expression of CK19 mRNA by using both OSNA and other
techniques, as well as protein expression. In the event that
CK19 expression is\95%, we will pilot assays to be used on
diagnostic biopsies of primary tumours to stratify them as
suitable, or not, for OSNA analysis of SLNB. Lastly, we
tested the concordance between matched primary tumour
and metastatic lymph node in CK19 expression.
METHODS
Tissue
A clinical cohort was assembled from the tissue banks of the
Universities of Liverpool and Copenhagen with appropriate
ethical approvals and consent. Clinicopathological character-
istics and results are summarised in Supplemental Table S1.
Cohort 1 (43 cases from Liverpool) met the criteria:
OSCC, clinical stage cT1N0 and cT2N0, formalin-fixed
paraffin-embedded (FFPE) and fresh-frozen tumour tissue
available. The OSNA assay interrogates fresh (or frozen)
sentinel lymph nodes[50 mg, preferably in their entirety.
This presented an ethical and logistic barrier as the lymph
nodes are required for histopathological staging, and
banked primary tumour samples were exclusively\50 mg
in T1/T2 OSCC. We therefore elected to analyse primary
tumour to establish CK19 expression using a number of
assays, excluding OSNA. Thirty-four of 43 had available
matched FFPE lymph nodes.
Cohort 2 (87 cases: 44 Liverpool and 43 Copenhagen)
met the criteria: OSCC,[50 mg snap-frozen primary
tumour tissue, most of these were cT3/4 cases.
Tissue Preparation and Handling
Cohort 1. Immunohistochemistry (IHC): 4-lm sections
were stained for CK19 protein by two methods: a mouse
monoclonal antibody (clone b170, Leica Biosystems) on a
Ventana Benchmark Ultra Autostainer (Ventana Medical
Systems, Inc.) at a dilution of 1:100 using standard
retrieval conditions (MMC1) and the detection polymer
Ultraview (Ventana Medical Systems, Inc.): a mouse
monoclonal antibody (clone RCK 108, Dako) diluted 1:100
and the EnVision FLEX system on an Autostainer Link 48
instrument (Dako) using high pH antigen retrieval. Nega-
tive controls omitted addition of the primary antibody.
In situ hybridization (ISH):CK19RNA ISH was performed
on 4-lm FFPE sections using proprietary reagents (RNAs-
cope, Advanced Cell Diagnostics, Inc.). Sections were
deparaffinised and pretreated with heat and protease before
hybridisation with target-specific probes: CK19, PPIB (con-
stitutively expressed endogenous gene; positive control) and
dapB (bacterial mRNA; negative control) in a dedicated
hybridization oven (HybEZ oven, Advanced Cell
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Diagnostics, Inc.). Probe hybridization was detected using the
chromogen 3,30-diaminobenzidine (DAB).
Both IHC and ISH techniques were optimized using
known positive (breast ductal carcinoma) and negative
tissue (lymph node). Tissue cores from controls constituted
a ‘‘control block’’—sections of which were mounted on
each test slide to ensure quality staining methods. The tests
were scored by two pathologists (MR & AT). Staining was
assessed by assigning an intensity score (0, no staining; 1,
weak; 2, moderate; 3, strong) and percentage of malignant
cells stained. These were used to calculate an H score
(product of intensity and percentage) but also classified in a
binary fashion (positive vs. negative).
RNA was prepared from fresh-frozen tissue of primary
tumours using an miRNeasy kit (Qiagen), and following
reverse transcription (cDNA kit, Applied Biosystems), a
CK19 qRT-PCR assay was performed with the following
primers/probe; Fwd: 50CACTACTACACGACCATCC
AGGAC 30, Rev: 50 CGGAAGTCATCTGCAGCCA 30,
Probe: 50 TAMRA-ACGGGCATTGTCGATCTGCAG
GAC-BHQ2. The qPCR reaction utilised the Universal
Master Mix II (Applied Biosystems), the thermal profile:
50 C for 2 min, 95 C for 10 min, 45 cycles of 95 C for
15 sec, and 60 C for 1 min, using a 7500 FAST instrument
(Applied Biosystems). The relative quantification (RQ)
value was calculated as: RQ = 2-DDCt, where Ct is the
cycle threshold for each target.
Cohort 2. OSNA: OSCC biopsies from cohort 2 with
mass between 50 and 600 mg were snap frozen and stored
at -80 C until shipment to Sysmex on dry ice. Samples
were processed according to manufacturer’s instructions
(Sysmex, Kobe, Japan) using a designated instrument (RD-
100i) and reagent system (LYNOAMP & LYNORHAG).
Individual tumour samples were placed in 4 ml of
homogenizing buffer LYNORHAG (0.2 M glycine-HCl
pH 3.5, 5% Brij35 and 20% DMSO), and homogenised for
60 s at 10,000 rpm with a Polytron System PT1300D
(Kinematica AG, Switzerland) and LYNOPREP blades to
prepare a homogeneous lysate. One milliliter of lysate was
centrifuged to remove cell debris and then further diluted
1:10 and 1:100 with LYNORHAG. The diluted lysates
were used directly for amplification without RNA extrac-
tion or purification. Isothermal amplification reactions were
performed at 65 C. The rise time required for precipitation
of magnesium pyrophosphate to reach a turbidity of 0.1 OD
at 465 nm was obtained for each sample and the number of
CK19 mRNA copies determined using a calibration curve.
OSNA was classified as following: (-) =\250 copies;
(-L) =\250 copies; (?) =[250 and\5000 copies,
(??) =[ 5000 copies; (??) or (?) were positive results,
whereas (-) or (-L) were negative.
RNA quality was analysed for negative (- or -L)
samples to exclude false negatives. OSNA lysates were
processed with the Qiagen RNeasy kit (Qiagen, Venlo,
Netherlands). Total RNA was quantified spectrophoto-
metrically (260/280 nm ratio). RNA integrity was assessed
using RNA Integrity Number (RIN) with a Bioanalyser
(Agilent, Santa Clara, CA).
CK19 IHC CK19 ISH
3567 Primary
3567 Metastasis
FIG. 1 A primary tumour that
shows weak, heterogeneous
CK19 positivity, and a
corresponding subcapsular
lymph node metastasis with
stronger CK19 staining. This
case illustrates the difficulty,
with either IHC or ISH, to offer
a confident diagnostic test to
identify cases from diagnostic
biopsy suitable for CK19 OSNA
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RNA was prepared from unused OSNA lysates and from
a separate aliquot of fresh-frozen tissue from the same
tumours, reverse transcribed and subject to CK19 qRT-
PCR assay as described above.
Interplate qRT-PCR variation was reduced by using the
DDCt method to normalise expression with respect to two
tumours that had previously been shown to highly express
CK19. A technical threshold of 0.005 9 the mean DCt of
CK19 IHC CK19 ISH
3392 Primary
3392 Metastasis
FIG. 2 A primary tumour that shows weak, heterogeneous CK19
positivity, and a corresponding lymph node metastasis with no CK19
staining. If this case had undergone SLNB analysis using CK19
OSNA, even with the apparent security of a ‘‘positive’’ primary
tumour, it is likely that a false-negative result would be returned with
consequent undertreatment and neck recurrence
TABLE 1 Test results for primary tumours with corresponding lymph node metastases
CK19 IHC CK19 ISH
Primary Metastasis Primary Metastasis
3123
3211
3352
3567
3392
3549
3464
3289
Red positive, blue negative, yellow not available, test failed quality assurance checks
R. Shaw et al.
the reference tumours was observed in two experiments
and was adopted to distinguish positive from negative
CK19 expression in all qRT-PCR experiments.
RESULTS
Cohort 1. Of 43 primary cT1/T2N0 tumours tested with
CK19 IHC, 21 (48.8%) were positive. Twenty-nine of 39
primary tumours evaluable in CK19 RNA ISH tests were
CK19 positive (74.4%); 4 failed quality assurance checks.
CK19 IHC was concordant with the CK19 RNA ISH in 26
of 39 cases (66.7%). For both tests, the staining was gen-
erally weak and heterogeneous (Figs. 1, 2) with positive
cases having H scores between 5 to 200. Discordant cases
(n = 13) had lower H scores (mean 42.7; range 5–160). Of
the 13 discordant results, 9 were positive in RNA ISH and
negative in IHC, reflecting higher sensitivity of RNA ISH.
Stage I/II OSCC was less likely to be positive by IHC than
stage III/IV (P\ 0.01). No such discrepancy was observed
for RNA ISH.
CK19 IHC and CK19 RNA ISH were concordant in 6 of
8 cases with corresponding lymph node metastases, omit-
ting two failed tests (Table 1). In one case, the primary
tumour was positive for both tests, but the corresponding
lymph node metastasis was negative (patient 3392; Fig. 2;
Table 1). Lymph nodes with no evidence of metastatic
carcinoma (n = 26) did not contain any CK19-positive
cells. There were no epithelial lymph node inclusions
(salivary or thyroid); however, in one case CK19 positive
perinodal salivary gland tissue was included in the section,
but this might have been dissected free prior to analysis in
an SLNB protocol.
Eighteen of 26 (69%) primary cT1/T2N0 tumour tissues
were positive for CK19 mRNA by qRT-PCR. CK19 qRT-
PCR was concordant with IHC in 16 of 26 cases (62%) and
with CK19 RNA ISH in 13 of 22 cases (59%; Table 2).
Discordant IHC cases tended to be positive by qRT-PCR
(7/10). By contrast, discordant ISH cases were equally
likely to be positive or negative (4/9 positive by qRT-
PCR); however, the ISH positives had lower H scores
(mean 33.0, range 5–160).
Cohort 2. Of 87 primary tumour samples analysed by
OSNA (Table 3), 7 were excluded because of compro-
mised RNA integrity (low RIN). Examination of
representative, H&E stained sections from the 43 Danish
samples identified 5 that did not contain tumour tissue by
pathological examination and 1 with compromised RNA
integrity. The remaining 4 were OSNA positive: 2 con-
tained oral epithelium and 2 contained salivary tissue. Of
76 tumour samples, 61 (80%) were CK19 mRNA positive
by OSNA, with no correlation for either tumour stage or
site (Supplementary Table S2).
Thirty-nine of the tumours from Liverpool had sufficient
tissue to allow extraction of mRNA from a separate portion
of the tumour. Of these, 23 (59%) were CK19 positive.
qRT-PCR data was concordant with OSNA data in 29 of 37
(78%) of cases, with OSNA proving the most sensitive test
in all 8 discordant cases. To investigate this more fully,
RNA from the OSNA tissue lysates from all 87 samples
was subject to qRT-PCR. Four samples were excluded
based on the low RNA levels (GAPDH amplification). Of
these samples, 56 of 83 (67%) were positive for CK19
expression, showing concordance with OSNA data in 70 of
81 (85%) of cases. All discordant cases demonstrated
positivity by OSNA but were negative by qRT-PCR.
CONCLUSIONS
CK19 expression is detectable for 50–80% of OSCC,
depending upon the assay used. RNA-ISH and qRT-PCR
are more sensitive than IHC, whereas OSNA appears to be
the most sensitive method. The prevalence of CK19
expression by OSNA is still, at 80%, insufficient to suggest
that OSNA could be used without prior screening of biopsy
tissue for CK19, because it could result in 20% of positive
lymph nodes being called as false-negative. CK19
expression in OSCC has been reported previously to range
from 53% to 91%.13,14 Our results confirm that CK19 can
be detected only in a subset of primary tumours. In this
regard, OSCC differs from breast, colorectal and stomach
sites, all adenocarcinomas, where CK19 OSNA has been
clinically validated. Although the chemistry and platform
available through OSNA appear to be well suited to clinical
use in being highly reliable, sensitive, and specific, the
gene target CK19 appears to offer insufficient expression in
OSCC for clinical application. Should a more appropriate
gene target (perhaps CK5 or 14) be available, it may be that
this would be suitable, subject to the appropriate and
necessary clinical validations.
TABLE 2 qRT-PCR concordance with IHC and ISH staining
IHC ISH
? - ? -
qRT-PCR ? 11 7 11 4
qRT-PCR - 3 5 5 2
TABLE 3 Distribution of CK19 mRNA expression by OSNA
OSNA No. of samples (%) %
(11) 45 (56) 65 (81)
(1) 20 (25)
(2) 12 (15) 15 (19)
(-L) 3 (4)
Total 80 (100)
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Although, theoretically, OSNA might be used on a fresh
biopsy sample to select CK19 positive tumours suitable for
OSNA assay in SLNB, concern remains that surrounding
oral mucosa or salivary gland could be included leading to
a false positive. CK19 mRNA ISH performed on an
existing FFPE diagnostic biopsy might be more convenient
and provide histological context, avoiding false positives.
However, our results show that CK19 mRNA ISH
expression was usually low and heterogeneous, limiting
diagnostic confidence and making the assay vulnerable to
interobserver variability. Consequently, we could not sug-
gest a reliable assay to stratify which tumours are
suitable for OSNA assay in SLNB.
In one case, the primary tumour was positive and the
matched lymph node metastasis was negative by both
CK19 ISH and IHC. Contamination in the neck structures
with ectopic salivary (0.9%) or thyroid tissue (1.5%) have
been reported either within or immediately surrounding
lymph nodes and could produce false positives in any
methodology that uses solid specimens.23,24 It may be that
careful dissection of single SLNB would eliminate this, but
again a validation study would be helpful.
Our data successfully incorporated a new assay (CK19
mRNA ISH) and shows potential clinical avenues in OSCC
for molecular diagnostics. We have CK19 data on 123
OSCC that effectively rules out the need for potentially
burdensome, and clinically risky, validation studies. The
international collaboration between two academic head and
neck cancer centres and industry augers well should a more
suitable assay become available. Such an assay might
additionally be applicable to cutaneous SCC and anogenital
SCC, which would increase the test’s commercial viability.
It is encouraging that OSNA assays with differing gene
targets, most recently with MMP7 (matrix-metallopro-
teinase 7) are available.25
The concept of intraoperative diagnostics in OSCC
remains attractive but awaits a suitable assay. At present,
SLNB analysis is based on evaluation of stepped serial
sections from only a proportion of the sentinel node, thus a
rapid technique examining the entire sentinel node for
tumour deposits may provide more accurate staging. An
automated intraoperative method also would avoid the
substantial additional workload for the pathology team
performing serial SLNB examination. In head and neck
oncology, intraoperative diagnostics appear even more
attractive than in melanoma and breast, because OSCC
remains largely a surgically treated disease and completing
all surgery in one operation would facilitate the wider
acceptance of SLNB.
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